[1] |
张路,李剑. 多中心型Castleman病的治疗进展[J]. 国际药学研究杂志,2017,44(2):162-166. DOI:10.13220/j.cnki.jipr.2017.02.014.
|
[2] |
SOUMERAI J D, SOHANI A R, ABRAMSON J S. Diagnosis and management of castleman disease[J]. Cancer Control:J Moffitt Cancer Cent,2014,21(4):266-278. DOI:10.1177/107327481402100403.
|
[3] |
DISPENZIERI A, FAJGENBAUM D C. Overview of Castleman disease[J]. Blood,2020,135(16):1353-1364. DOI:10.1182/blood.2019000931.
|
[4] |
CASPER C, TELTSCH D Y, ROBINSON Jr D,et al. Clinical characteristics and healthcare utilization of patients with multicentric Castleman disease[J]. Br J Haematol,2015,168(1):82-93. DOI:10.1111/bjh.13111.
|
[5] |
ZHOU X P, WEI J Y, LOU Y J,et al. Salvage therapy with lenalidomide containing regimen for relapsed/refractory Castleman disease:a report of three cases[J]. Front Med,2017,11(2):287-292. DOI:10.1007/s11684-017-0510-2.
|
[6] |
SZTURZ P, ADAM Z, CHOVANCOVá J,et al. Lenalidomide:a new treatment option for Castleman disease[J]. Leuk Lymphoma,2012,53(10):2089-2091. DOI:10.3109/10428194.2011.621564.
|
[7] |
SZTURZ P, ADAM Z, REHAK Z,et al. Salvage lenalidomide in four rare oncological diseases[J]. Tumori,2013,99(5):e251-256. DOI:10.1700/1377.15326.
|
[8] |
CAI S S, ZHONG Z D, LI X,et al. Treatment of multicentric Castleman disease through combination of tocilizumab,lenalidomide and glucocorticoids:case report[J]. Medicine,2019,98(46):e17681. DOI:10.1097/MD.0000000000017681.
|
[9] |
ZHANG Y, SUO S S, YANG H J,et al. Clinical features and treatment of 7 Chinese TAFRO syndromes from 96 de novo Castleman diseases:a 10-year retrospective study[J]. J Cancer Res Clin Oncol,2020,146(2):357-365. DOI:10.1007/s00432-019-03120-w.
|
[10] |
CASTLEMAN B, IVERSON L, MENENDEZ V P. Localized mediastinal lymphnode hyperplasia resembling thymoma[J]. Cancer,1956,9(4):822-830.
|
[11] |
ZHANG L, LI Z Y, CAO X X,et al. Clinical spectrum and survival analysis of 145 cases of HIV-negative Castleman's disease:renal function is an important prognostic factor[J]. Sci Rep,2016,6:23831. DOI:10.1038/srep23831.
|
[12] |
DISPENZIERI A, ARMITAGE J O, LOE M J,et al. The clinical spectrum of Castleman's disease[J]. Am J Hematol,2012,87(11):997-1002. DOI:10.1002/ajh.23291.
|
[13] |
DE MARCHI G, DE VITA S, FABRIS M,et al. Systemic connective tissue disease complicated by Castleman's disease:report of a case and review of the literature[J]. Haematologica,2004,89(4):ECR03.
|
[14] |
LEGER-RAVET M B, PEUCHMAUR M, DEVERGNE O,et al. Interleukin-6 gene expression in Castleman's disease[J]. Blood,1991,78(11):2923-2930.
|
[15] |
VAN RHEE F, WONG R S, MUNSHI N,et al. Siltuximab for multicentric Castleman's disease:a randomised,double-blind,placebo-controlled trial[J]. Lancet Oncol,2014,15(9):966-974. DOI:10.1016/S1470-2045(14)70319-5.
|
[16] |
SOULIER J, GROLLET L, OKSENHENDLER E,et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric castleman's disease[J]. Blood,1995,86(4):1276-1280. DOI:10.1182/blood.V86.4.1276.bloodjournal8641276.
|
[17] |
TALAT N, BELGAUMKAR A P, SCHULTE K M. Surgery in Castleman's disease:a systematic review of 404 published cases[J]. Ann Surg,2012,255(4):677-684. DOI:10.1097/SLA.0b013e318249dcdc.
|
[18] |
CHRONOWSKI G M, HA C S, WILDER R B,et al. Treatment of unicentric and multicentric Castleman disease and the role of radiotherapy[J]. Cancer,2001,92(3):670-676.
|
[19] |
王娟,梁利杰,王耀美,等. 59例Castleman病患者的临床病理特征及诊治分析[J]. 中华血液学杂志,2020,41(8):666-670.
|
[20] |
YU L, TU M F, CORTES J,et al. Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease[J]. Blood,2017,129(12):1658-1668. DOI:10.1182/blood-2016-11-748855.
|
[21] |
VAN RHEE F, ROTHMAN M, HO K F,et al. Patient-reported outcomes for multicentric castleman's disease in a randomized,placebo-controlled study of siltuximab[J]. Patient,2015,8(2):207-216. DOI:10.1007/s40271-015-0120-5.
|
[22] |
CASPER C, CHATURVEDI S, MUNSHI N,et al. Analysis of inflammatory and anemia-related biomarkers in a randomized,double-blind,placebo-controlled study of siltuximab (anti-IL6 monoclonal antibody) in patients with multicentric castleman disease[J]. Clin Cancer Res,2015,21(19):4294-4304. DOI:10.1158/1078-0432.CCR-15-0134.
|
[23] |
VERNON M, ROBINSON D Jr, TRUNDELL D,et al. Deriving health utility values from a randomized,double-blind,placebo-controlled trial of siltuximab in subjects with multicentric Castleman's disease[J]. Curr Med Res Opin,2016,32(7):1193-1200. DOI:10.1185/03007995.2016.1164675.
|
[24] |
LEE F C, MERCHANT S H. Alleviation of systemic manifestations of multicentric Castleman's disease by thalidomide[J]. Am J Hematol,2003,73(1):48-53. DOI:10.1002/ajh.10310.
|
[25] |
TATEKAWA S, UMEMURA K, FUKUYAMA R,et al. Thalidomide for tocilizumab-resistant ascites with TAFRO syndrome[J]. Clin Case Rep,2015,3(6):472-478. DOI:10.1002/ccr3.284.
|
[26] |
ZHANG L, ZHAO A L, DUAN M H,et al. Phase 2 study using oral thalidomide-cyclophosphamide-prednisone for idiopathic multicentric Castleman disease[J]. Blood,2019,133(16):1720-1728. DOI:10.1182/blood-2018-11-884577.
|
[27] |
GHOSH N, GRUNWALD M R, FASAN O,et al. Expanding role of lenalidomide in hematologic malignancies[J]. Cancer Manag Res,2015,7:105-119. DOI:10.2147/CMAR.S81310.
|